Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04)

Next Previous
Search
Trial Profile

An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxotemitide (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Tumour infiltrating lymphocytes
  • Indications Leiomyosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ATLAS-IT-04
  • Sponsors Lytix Biopharma

    • Most Recent Events

    • 29 Feb 2024 According to Lytix Biopharma media release, results from this ATLAS-IT-04 study were published in a paper entitled LTX315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor-specific T cells in patients with metastatic soft tissue sarcoma, the paper was published in OncoImmunology.
    • 15 Aug 2022 Results published in the Lytix Biopharma Media Release.
    • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top